Skip to main content
Delfa

← All assets

CAD106

7 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

7

Ongoing

0

Recruiting

0

Completed

6

Sites

180

Countries

14

Endpoints

59

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 59 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
5
Phase 2/3
1

Trials by status

Completed
6
Terminated
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Amyloid biomarkers
16
Global cognition
12
Other (unclassified)
9
Neuroimaging
6
Safety / tolerability / PK
6
Memory
4
Behavior / neuropsychiatric
2
Tau biomarkers
2
Neurodegeneration biomarkers
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 8 of 59 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

2

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

2

Amyloid PET CentiloidAmyloid

2

Neurofilament light (NfL)Neurodeg.

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

7 of 7

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
GS1A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

CAD106, Umibecestat

Alzheimer’s disease

MMSE ≥24Ph 2/3Terminated129Apr 2020-results
NCT01097096Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

CAD106

Alzheimer’s disease

Alzheimer's diseasePh 2Completed31Dec 2012-
NCT00795418Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

CAD106

Alzheimer’s disease

Alzheimer's diseasePh 2Completed10Nov 20101
NCT01023685To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

CAD106

Alzheimer’s disease

-Ph 2Completed8Feb 20121
NCT00956410To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

CAD106

Alzheimer’s disease

Age 40-85Ph 2Completed4Jun 20111
NCT00733863Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.

CAD106

Alzheimer’s disease

Alzheimer's diseasePh 2Completed4Feb 20101
NCT00411580Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)

CAD106

Alzheimer’s disease

mild-to-moderate ADPh 1Completed3Dec 20081

Showing 1-7 of 7 trials